ArticleFrontiers in bioinformatics2026
Delineating novel diagnostic biomarkers and therapeutic targets for oral submucosal fibrosis: an integrative multi-omics and machine learning approach.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral submucosal fibrosis (OSF) is a chronic and progressive disorder, caused by chewing areca nuts, affecting the oral cavity and oropharynx. OSF is characterized by severe symptoms like severe burning sensation, restricted mouth opening, etc. Given the multifactorial and poorly understood molecular basis of the disease, there is a need for novel biomarkers and therapeutic targets. Method: We downloaded 3 RNA-seq, two microarray, one epigenomic, and one single-cell RNA-seq datasets from the gene expression omnibus database. Differentially expressed genes (DEGs) were characterized using DESeq2. Several analyses, including gene enrichment, immune cell infiltration, protein-protein interaction, and more, were performed. Machine learning models were developed using all DEGs and top5 selected features with leave one out cross validation technique. Independent validations were performed using two microarray datasets with appropriate statistical measures. Epigenetic analysis revealed hyper- and hypomethylated genes based on delta-beta values, and an integrative analysis of the transcriptome and methylome was performed to obtain key biomarkers. Single-cell analysis was performed to identify key cell types showing higher DEG expression. Result: DESeq2 analysis identified 29 upregulated and 15 downregulated DEGs. Upregulated DEGs show enrichment for the inflammatory, metabolic, and signaling processes, whereas downregulated DEGs were largely associated with metabolic processes. Immune cell enrichment analysis using CIBERSORTx shows higher enrichment of "T cells," "mast cells," and "macrophages" in OSF patients. We validated our findings in two independent microarray datasets and observed a similar gene expression pattern of DEGs. Machine learning performed using top5 features where Random Forest model achieved AUROC of 0.99 and AUPRC of 0.99. Further, ROC analysis and AUC plot show that DEGs can discriminate OSF patients from the normal population with high AUROC. Integrative analysis of methylation and transcriptomic data identified 11 genes as potential diagnostic biomarkers and therapeutic targets. Finally, single-cell analysis elucidates the higher expression of DEGs in "keratinocyte", "epithelial cells" and "dendritic cells". Conclusion: Integrative analysis identified 11 gene signatures as potential early diagnostic biomarkers and therapeutic targets for the OSF. Furthermore, the study hints towards mechanistic insight into potential mechanism leading to oral cancer. All the codes and ML models are provided at our GitHub repository https://github.com/agrawalpiyush-srm/OSF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.